146 related articles for article (PubMed ID: 30055549)
1. Melatonin Improves Behavioral and Biochemical Outcomes in a Rotenone-Induced Rat Model of Parkinson's Disease.
Rasheed MZ; Andrabi SS; Salman M; Tabassum H; Shaquiquzzaman M; Parveen S; Parvez S
J Environ Pathol Toxicol Oncol; 2018; 37(2):139-150. PubMed ID: 30055549
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats.
Bassani TB; Gradowski RW; Zaminelli T; Barbiero JK; Santiago RM; Boschen SL; da Cunha C; Lima MM; Andreatini R; Vital MA
Brain Res; 2014 Dec; 1593():95-105. PubMed ID: 25301688
[TBL] [Abstract][Full Text] [Related]
4. Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson's disease.
Khurana N; Gajbhiye A
Neurotoxicology; 2013 Dec; 39():57-64. PubMed ID: 23994302
[TBL] [Abstract][Full Text] [Related]
5. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Tapias V; Cannon JR; Greenamyre JT
J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
[TBL] [Abstract][Full Text] [Related]
6. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Brain Res; 2016 Feb; 1633():115-125. PubMed ID: 26740407
[TBL] [Abstract][Full Text] [Related]
7. Protective role of apigenin on rotenone induced rat model of Parkinson's disease: Suppression of neuroinflammation and oxidative stress mediated apoptosis.
Anusha C; Sumathi T; Joseph LD
Chem Biol Interact; 2017 May; 269():67-79. PubMed ID: 28389404
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of indole-3-carbinol on the rotenone rat model of Parkinson's disease: Impact of the SIRT1-AMPK signaling pathway.
Mohamad KA; El-Naga RN; Wahdan SA
Toxicol Appl Pharmacol; 2022 Jan; 435():115853. PubMed ID: 34973289
[TBL] [Abstract][Full Text] [Related]
9. Saxagliptin: a novel antiparkinsonian approach.
Nassar NN; Al-Shorbagy MY; Arab HH; Abdallah DM
Neuropharmacology; 2015 Feb; 89():308-17. PubMed ID: 25446674
[TBL] [Abstract][Full Text] [Related]
10. Effect of Bacille-Calmette-Guerin vaccine against rotenone-induced Parkinson's disease: Role of neuroinflammation and neurotransmitters.
Yedke NG; Soni D; Kumar P
Fundam Clin Pharmacol; 2024 Jun; 38(3):538-549. PubMed ID: 38041521
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease.
Badawi GA; Abd El Fattah MA; Zaki HF; El Sayed MI
Inflammopharmacology; 2017 Jun; 25(3):369-382. PubMed ID: 28258522
[TBL] [Abstract][Full Text] [Related]
12. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats.
Lin CH; Huang JY; Ching CH; Chuang JI
J Pineal Res; 2008 Mar; 44(2):205-13. PubMed ID: 18289173
[TBL] [Abstract][Full Text] [Related]
13. Role of L-thyroxin in counteracting rotenone induced neurotoxicity in rats.
Salama M; Helmy B; El-Gamal M; Reda A; Ellaithy A; Tantawy D; Mohamed M; El-Gamal A; Sheashaa H; Sobh M
Environ Toxicol Pharmacol; 2013 Mar; 35(2):270-7. PubMed ID: 23357603
[TBL] [Abstract][Full Text] [Related]
14. The rotenone-induced rat model of Parkinson's disease: behavioral and electrophysiological findings.
von Wrangel C; Schwabe K; John N; Krauss JK; Alam M
Behav Brain Res; 2015 Feb; 279():52-61. PubMed ID: 25446762
[TBL] [Abstract][Full Text] [Related]
15. p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease.
Wu F; Wang Z; Gu JH; Ge JB; Liang ZQ; Qin ZH
Neurochem Int; 2013 Sep; 63(3):133-40. PubMed ID: 23714208
[TBL] [Abstract][Full Text] [Related]
16. Preliminary optimization of a Chinese herbal medicine formula based on the neuroprotective effects in a rat model of rotenone-induced Parkinson's disease.
Bao XX; Ma HH; Ding H; Li WW; Zhu M
J Integr Med; 2018 Jul; 16(4):290-296. PubMed ID: 29866613
[TBL] [Abstract][Full Text] [Related]
17. Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.
Mack JM; Schamne MG; Sampaio TB; Pértile RA; Fernandes PA; Markus RP; Prediger RD
Oxid Med Cell Longev; 2016; 2016():3472032. PubMed ID: 27829983
[TBL] [Abstract][Full Text] [Related]
18. A delivery strategy for rotenone microspheres in an animal model of Parkinson's disease.
Huang J; Liu H; Gu W; Yan Z; Xu Z; Yang Y; Zhu X; Li Y
Biomaterials; 2006 Feb; 27(6):937-46. PubMed ID: 16118017
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective and Therapeutic Effect of Caffeine on the Rat Model of Parkinson's Disease Induced by Rotenone.
Khadrawy YA; Salem AM; El-Shamy KA; Ahmed EK; Fadl NN; Hosny EN
J Diet Suppl; 2017 Sep; 14(5):553-572. PubMed ID: 28301304
[TBL] [Abstract][Full Text] [Related]
20. Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease.
Falk T; Zhang S; Sherman SJ
Neurosci Lett; 2009 Jul; 458(2):49-52. PubMed ID: 19442875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
